Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gregory Zarbis-Papastoitsis"'
Autor:
Gregory Zarbis-Papastoitsis
Publikováno v:
Immuno Oncology Insights. 2:345-348
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9d8c1f3110a6baef70904430fa6fec5
https://doi.org/10.18609/ioi.2021.041
https://doi.org/10.18609/ioi.2021.041
Autor:
Eric Furfine, Karen L Tubridy, Kathryn Golden, Fiona Soong, Gregory Zarbis-Papastoitsis, Marianne Magill, Michael H Goldstein, Jennifer Agahigian, Anne Marie Salapatek, Joseph Kovalchin, Gary Sternberg, Abbie Celniker
Publikováno v:
Eye & Contact Lens: Science & Clinical Practice. 41:145-155
OBJECTIVES Many allergic conjunctivitis (AC) patients are inadequately treated with conventional therapies or require steroids. EBI-005 was developed to address the late phase allergic response. This study's objectives were to evaluate two adapted cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ff9f3a1e86020e7b8d3cfb4cbebd2d0
https://doi.org/10.1097/icl.0000000000000152
https://doi.org/10.1097/icl.0000000000000152
Autor:
Gregory Zarbis-Papastoitsis, Allyson Masci, Christoph Thomas, Sharon A. Townson, Olga Kiner, Kathryn Golden, Jinzhao Hou, Joseph Kovalchin, Yanqun Shu, Emily Belcher Schirmer, Eric Furfine, K. Christopher Garcia, Thomas M. Barnes, Bracken M. King
Publikováno v:
Proceedings of the National Academy of Sciences. 110:3913-3918
IL-1 is a key inflammatory and immune mediator in many diseases, including dry-eye disease, and its inhibition is clinically efficacious in rheumatoid arthritis and cryopyrin-associated periodic syndromes. To treat ocular surface disease with a topic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a402ff48f7d311efbbe60a2d03ab1268
https://doi.org/10.1073/pnas.1217996110
https://doi.org/10.1073/pnas.1217996110
Autor:
Gregory Zarbis-Papastoitsis, Emily Belcher Schirmer, Michael Christopher Kuczewski, Blanca Lain
Publikováno v:
Biotechnology Journal. 6:56-65
Advances in single-use technologies can enable greater speed, flexibility, and a smaller footprint for multi-product production facilities, such as at a contract manufacturer. Recent efforts in the area of cell line and media optimization have result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab27793771cfbebf157556382fad1622
https://doi.org/10.1002/biot.201000292
https://doi.org/10.1002/biot.201000292
Autor:
Gregory Zarbis-Papastoitsis, Emily Belcher Schirmer, Alec J. Murillo, Jinzhao Hou, Allyson Masci, Kathryn Collins, Kathryn Golden, Jin Xu, Joseph Kovalchin, Sri Hari Raju Mulagapati, Patricia Lowden, Jesse Milling
Publikováno v:
Biotechnology journal. 8(8)
Through a parallel approach of tracking product quality through fermentation and purification development, a robust process was designed to reduce the levels of product-related species. Three biochemically similar product-related species were identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c4a4aff7adfade469a25a4ce58f924
https://pubmed.ncbi.nlm.nih.gov/23913906
https://pubmed.ncbi.nlm.nih.gov/23913906
Autor:
John Chon, Gregory Zarbis-Papastoitsis
Publikováno v:
New biotechnology. 28(5)
Sales of monoclonal antibody (mAbs) therapies exceeded $ 40 billion in 2010 and are expected to reach $ 70 billion by 2015. The majority of the approved antibodies are targeting cancer and autoimmune diseases with the top 5 grossing antibodies popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76db6858c84732b12f85ea98df8f046c
https://pubmed.ncbi.nlm.nih.gov/21515428
https://pubmed.ncbi.nlm.nih.gov/21515428